THC Tenet Healthcare Corporation

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Based on the average brokerage recommendation (ABR), Tenet (THC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

EHC posts strong Q2 with higher EPS, revenue growth, and a raised 2025 outlook, along with shares gaining 7.4%.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.